Relapsing Remitting Multiple Sclerosis: Clinical Trials

1 trial for Relapsing Remitting Multiple Sclerosis, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

1 completed. 1 Early Phase 1.

By phase and status

PhaseTrialsStatus
Early Phase 11Completed 1

Follow Relapsing Remitting Multiple Sclerosis: new trials by email Literature Review of Relapsing Remitting Multiple Sclerosis trials Research Report on Relapsing Remitting Multiple Sclerosis

Trials (filtered) newest first · largest first

All 1 trial

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Melatonin in Patients With Multiple Sclerosis (MS).
3 mg Melatonin, 5 mg Melatonin - Relapsing Remitting Multiple Sclerosis
Early Phase 1CompletedProvidence Health & Services302018-05-092025-03-30

Narrower conditions

Multiple Sclerosis (1)  ·  Multiple Sclerosis, Relapsing-Remitting (1)

Broader conditions

Autoimmune Diseases (1)  ·  Autoimmune Diseases of the Nervous System (1)  ·  Demyelinating Autoimmune Diseases, CNS (1)  ·  Demyelinating Diseases (1)  ·  Immune System Diseases (1)  ·  Nervous System Diseases (1)

Interventions

Melatonin (1)

Sponsors

Providence Health & Services (1)

Countries

United States (1)

Top investigators

Kyle Smoot, MD (1)

Results publications

PMID 35355991, PMID 39126937